Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01097304 · ClinicalTrials.gov registry record · Phase 2
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01097304: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01097304 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01097304, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well ursodiol works in treating patients with Barrett esophagus or cells that look abnormal under a microscope but are not cancer (low-grade dysplasia). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of ursodiol may keep cancer for forming in patients with Barrett esophagus or low-grade dysplasia.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Ursodiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01097304
The ClinicalTrials.gov registry entry for NCT01097304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01097304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01097304 about?
NCT01097304 is a clinical study titled "Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia". This pilot phase II trial studies how well ursodiol works in treating patients with Barrett esophagus or cells that look abnormal under a microscope but are not cancer (low-grade dysplasia). Chemoprevention is the use of certain drugs to keep cancer from forming. The use of ursodiol may keep cancer ...
What is the current status of trial NCT01097304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2010-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01097304?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ursodiol (DRUG).
Who is sponsoring clinical trial NCT01097304?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.